Do that to me one more time! What kind of trial replications do we need?
Lüdtke R (2008) · Complementary Therapies in Medicine · n=0
Study Profile
- Design
- invited editorial on the methodological need for and design of replication trials in leech therapy and complementary medicine generally (Karl and Veronica Carstens Foundation, Germany)
- Sample size (n)
- 0
- Intervention
- Editorial discussion of replication-trial design - direct replication versus methodologically improved replication, sham control issues, meta-analytic considerations
- Comparator
- Editorial framework - not an empirical comparison
- Primary endpoint
- Methodological recommendations for future leech therapy replication trials
- Primary result
- Recommends replication trials that are methodologically improved over the original Michalsen 2003 design - in particular adding sham control where ethically feasible - rather than purely direct replication; flags Andereya 2008 Acta Orthopaedica's artificial-leech control as an example of progress
- Follow-up duration
- not applicable (editorial)
- PMID
- 18638707
Key Findings
- Editorial by Karl and Veronica Carstens Foundation methodologist Rainer Lüdtke, co-author of the Michalsen 2003 landmark RCT
- Argues for methodologically improved replication trials (especially adding sham control) over direct replication
- Specifically discusses leech therapy in the context of broader complementary-medicine trial replication
- Influenced the design of subsequent sham-controlled trials including Hohmann 2014 and the ongoing ELECT 2025 trial
- Provides methodological framing for understanding why the field has progressively shifted from open-label to sham-controlled designs
Limitations
- Editorial only - not primary evidence
- No empirical data
- Reflects 2008 methodological state-of-the-art - subsequent literature has advanced
- Single-author opinion piece
- No GRADE rating
Clinical Implications
Lüdtke 2008 is an important methodological reference for understanding the trajectory of the leech-therapy RCT literature. It documents the moment when the field recognized that further open-label replication was less valuable than sham-controlled and methodologically-improved designs. For ASH editorial-board purposes, this editorial provides historical context for the moderate GRADE rating applied to the knee OA evidence base: the field acknowledges that current evidence is moderate-quality precisely because the foundational Michalsen 2003 trial was open-label, and the subsequent improvement trajectory (Andereya 2008 artificial leech, Hohmann 2014 sham, ELECT 2025 multicenter sham) has not yet fully closed the gap.
Related Trials
Effectiveness of leech therapy in osteoarthritis of the knee: a randomized, controlled trial
Michalsen A, Klotz S, Lüdtke R, Moebus S, Spahn G, Dobos GJ (2003)
Leech therapy for symptomatic treatment of knee osteoarthritis: results and implications of a pilot study
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O (2006)
Comparison of modern leech therapy with intra-articular hyaluronic acid injections for symptomatic relief of knee osteoarthritis
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O, Andereya S (2008)
Effectiveness of home-based cupping massage compared to progressive muscle relaxation in patients with chronic neck pain — a randomized controlled trial (Note: companion knee OA study)
Lauche R, Cramer H, Langhorst J, Dobos G, Michalsen A (2014)